Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer

BACKGROUND: Antibodies against the programmed death-1 (PD-1) receptor and its ligand (PD-L1) have been recently approved for small-cell lung cancer (SCLC) treatment. Circulating tumour cells (CTCs) have emerged as an appealing liquid biopsy candidate that could enhance treatment decision-making in s...

Descripción completa

Detalles Bibliográficos
Autores principales: Acheampong, Emmanuel, Abed, Afaf, Morici, Michael, Spencer, Isaacs, Beasley, Aaron B., Bowyer, Samantha, Asante, Du-Bois, Lomma, Chris, Lin, Weitao, Millward, Michael, Gray, Elin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988079/
https://www.ncbi.nlm.nih.gov/pubmed/35399573
http://dx.doi.org/10.21037/tlcr-21-819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988079/
https://www.ncbi.nlm.nih.gov/pubmed/35399573
http://dx.doi.org/10.21037/tlcr-21-819

Ejemplares similares